日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial

不可切除肝细胞癌患者接受 tremelimumab 联合 durvalumab 治疗和 durvalumab 单药治疗的免疫介导不良事件和总生存期:HIMALAYA III 期随机临床试验

Lau, George; Sangro, Bruno; Cheng, Ann-Lii; Kudo, Masatoshi; Kelley, Robin Kate; Tak, Won Young; Gasbarrini, Antonio; Reig, Maria; Lim, Ho Yeong; Tougeron, David; De Toni, Enrico N; Tam, Vincent C; Mody, Kabir; Gong, Jun; Crysler, Oxana V; Sukeepaisarnjaroen, Wattana; Lipatov, Oleg; Morimoto, Manabu; Archambeaud, Isabelle; Burgio, Valentina; Phuong, Le Thi Tuyet; Chao, Yee; Peron, Jean-Marie; Berres, Marie-Luise; Ko, Yoo-Joung; Ran, Di; Makowsky, Mallory; Negro, Alejandra; Abou-Alfa, Ghassan K

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers

RO7119929(一种口服TLR7激动剂前药)在晚期原发性或转移性肝癌患者中的首次人体I期研究

Yoo, Changhoon; Fabregat-Franco, Carles; Lin, Chia-Chi; Qvortrup, Camilla; Oh, Do-Youn; Yau, Thomas; Kim, Hyung-Don; Castet, Florian; Ponz Sarvise, Mariano; Hsu, Chiun; Rohrberg, Kristoffer Staal; Lichtenegger, Felix Sebastian; Franjkovic, Izolda; Kratochwil, Nicole A; Bessa, Juliana; Rossmann, Eva; Schwalie, Petra C; Rieder, Natascha; Pöschinger, Thomas; Sie, Christina Godfried; Dettling, Steffen; Schlenker, Ramona; Jiang, Tianyi; Dai, Congqi; Yun, Hongying; Hall, Elia; Yeo Te-Ying, Audrey; Hoves, Sabine; Cannarile, Michael A; Schiff, Christina; Sangro, Bruno

A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells

肝脏基因特征将慢性病毒性肝炎患者的肝癌风险与肝内IgA浆细胞联系起来

Van Renne, Nicolaas; Ballet, Fleur; Van Hees, Stijn; Cuypers, Bart; Furquim d'Almeida, Arno; Vanderlinden, Axelle; Meysman, Pieter; Feld, Jordan J; Sangro Del Alcázar, Paloma; Bourgeois, Stefan; Sprengers, Dirk; Robaeys, Geert; Vonghia, Luisa; Michielsen, Peter; Francque, Sven; Sangro, Bruno; Cain, Owen; Elsharkawy, Ahmed M; De Man, Rob; Boonstra, Andre; Janssen, Harry L A; Driessen, Ann; Laukens, Kris; Vanwolleghem, Thomas

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy

接受联合放射免疫疗法治疗的肝细胞癌患者新抗原的免疫原性

Aparicio, Belén; Silva, Leyre; Ruiz, Marta; Llópiz, Diana; Repáraz, David; Theunissen, Patrick; Tamayo, Ibon; Egea, Josune; Igea, Ana; Smerdou, Cristian; Peñas, Maria; Perpiñá, Cristina; Matilla, Ana; Varela, María; Reig, Maria; de la Torre-Alaez, Manuel; Argemí, Josepmaria; Sangro, Bruno; Hervás-Stubbs, Sandra; Sarobe, Pablo

Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.

三叶因子-3是肝母细胞瘤中缺氧触发的促肿瘤因子。

Martínez-Pérez Luz A, Latasa M Ujue, Uriarte Iker, López-Pascual Amaya, Elurbide Jasmin, Strnad Pavel, Frankova Sona, Sticova Eva, Fabian Ondrej, Arechederra Maria, Santamaria Eva, Argemi Josepmaria, Sangro Bruno, Foglia Beatrice, Parola Maurizio, Gutiérrez-Angulo Melva, Cairo Stefano, Bataller Ramón, Sancho-Bru Pau, Martinez-Chantar Maria L, Marin Jose J G, Castaneda Andrea, Armengol Carolina, Berasain Carmen, Fernandez-Barrena Maite G, Ávila Matias A

Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

影像学在肝细胞癌局部和区域治疗的分期、治疗计划制定和监测中的应用:EORTC 和 ESGAR 的共识建议

Öcal, Osman; Zech, Christoph Johannes; Bali, Maria Antonietta; Pasquier, David; Mottaghy, Felix; Einspieler, Ingo; Kartalis, Nikolaos; Bargellini, Irene; Iezzi, Roberto; Denecke, Timm; Kunz, Wolfgang Gerhard; Gebauer, Bernhard; Wege, Henning; Cannella, Roberto; Oprea-Lager, Daniela Elena; Vogel, Arndt; Sangro, Bruno; Seidensticker, Max

Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

更正:肝细胞癌局部和区域治疗的分期、治疗计划和监测中的影像学应用:EORTC 和 ESGAR 的共识建议

Öcal, Osman; Zech, Christoph Johannes; Bali, Maria Antonietta; Pasquier, David; Mottaghy, Felix; Einspieler, Ingo; Kartalis, Nikolaos; Bargellini, Irene; Iezzi, Roberto; Denecke, Timm; Kunz, Wolfgang Gerhard; Gebauer, Bernhard; Wege, Henning; Cannella, Roberto; Oprea-Lager, Daniela Elena; Vogel, Arndt; Sangro, Bruno; Seidensticker, Max

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

度伐利尤单抗联合或不联合贝伐珠单抗治疗肝细胞癌经动脉化疗栓塞术(EMERALD-1):一项多区域、随机、双盲、安慰剂对照的3期研究

Sangro, Bruno; Kudo, Masatoshi; Erinjeri, Joseph P; Qin, Shukui; Ren, Zhenggang; Chan, Stephen L; Arai, Yasuaki; Heo, Jeong; Mai, Anh; Escobar, Jose; Lopez Chuken, Yamil Alonso; Yoon, Jung-Hwan; Tak, Won Young; Breder, Valeriy V; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Peron, Jean-Marie; Nguyen, Quang T; Yan, Lunan; Chiu, Chang-Fang; Santos, Florinda A; Veluvolu, Anil; Thungappa, Satheesh Chiradoni; Matos, Marco; Żotkiewicz, Magdalena; Udoye, Stephanie I; Kurland, John F; Cohen, Gordon J; Lencioni, Riccardo

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

移植前使用免疫检查点抑制剂对肝细胞癌移植后结局的影响:系统评价和个体患者数据荟萃分析

Rezaee-Zavareh, Mohammad Saeid; Yeo, Yee Hui; Wang, Tielong; Guo, Zhiyong; Tabrizian, Parissa; Ward, Stephen C; Barakat, Fatma; Hassanein, Tarek I; Dave, Shravan; Ajmera, Veeral; Bhoori, Sherrie; Mazzaferro, Vincenzo; Chascsa, David M H; Liu, Margaret C; Aby, Elizabeth S; Lake, John R; Sogbe, Miguel; Sangro, Bruno; Abdelrahim, Maen; Esmail, Abdullah; Schmiderer, Andreas; Chouik, Yasmina; Rudolph, Mark; Sohal, Davendra; Giudicelli, Heloise; Allaire, Manon; Akce, Mehmet; Guadagno, Jessica; Tow, Clara Y; Massoumi, Hatef; De Simone, Paolo; Kang, Elise; Gartrell, Robyn D; Martinez, Mercedes; Paz-Fumagalli, Ricardo; Toskich, Beau B; Tran, Nguyen H; Solino, Gabriela Azevedo; Poltronieri Pacheco, Dra Mariana; Kalman, Richard S; Agopian, Vatche G; Mehta, Neil; Parikh, Neehar D; Singal, Amit G; Yang, Ju Dong

Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice

经基因工程改造,表达靶向糖蛋白聚糖3的HLA-A2限制性鼠源T细胞受体的人类T细胞,可有效控制小鼠体内的人类肝细胞癌。

Vercher, Enric; Covo-Vergara, Ángela; Conde, Enrique; Hernández-Rueda, Mercedes; Elizalde, Edurne; Mancheño, Uxua; Glez-Vaz, Javier; Tamayo-Uria, Ibon; García-García, Maritza R; Ferrer-Roig, Marta; Marañón-Lopez, Javier; Repáraz, David; Ruiz, Marta; López-Díaz de Cerio, Ascensión; Inogés, Susana; Iñarrairaegui, Mercedes; Lasarte, Juan J; Sangro, Bruno; Sarobe, Pablo; Hervas-Stubbs, Sandra